10 completed, 2 terminated, 1 withdrawn. 10 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 8, Terminated 2 |
| Phase 1 | 7 | Completed 5, Terminated 1, Withdrawn 1 |
Follow Gemin X: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Obatoclax for Systemic Mastocytosis Obatoclax Mesylate - Leukemia, Systemic Mastocytosis | Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2009-06-01 | 2011-11-04 |
| A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma Obatoclax Mesylate, Temozolomide - Metastatic Melanoma | Phase 1 / Phase 2 | Terminated | Gemin X | 1 | 2008-06-01 | 2016-07-22 |
| A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Obatoclax, Carboplatin/etoposide - Extensive-stage Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Gemin X | 218 | 2008-05-01 | 2016-07-21 |
| Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML) Obatoclax - AML | Phase 2 | Completed | Gemin X | 18 | 2008-04-01 | 2013-08-26 |
| Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) Obatoclax mesylate, Rituximab - Lymphoma, Follicular | Phase 2 | Completed | Gemin X | 7 | 2007-03-01 | 2016-07-22 |
| Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas GMX1777 - Solid Tumors and Lymphomas | Phase 1 | Withdrawn | Gemin X | 2007-03-01 | 2013-08-28 | |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS) Obatoclax mesylate (GX15-070MS) - Myelodysplastic Syndromes | Phase 2 | Completed | Gemin X | 24 | 2006-12-01 | 2013-08-26 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer Obatoclax mesylate 250 ml, Docetaxel - Lung Cancer | Phase 1 / Phase 2 | Completed | Gemin X | 47 | 2006-10-01 | 2016-07-21 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) Obatoclax mesylate, Bortezomib - Mantle-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Gemin X | 24 | 2006-10-01 | 2016-07-21 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia Obatoclax mesylate (GX15-070MS) - Myelofibrosis | Phase 2 | Completed | Gemin X | 22 | 2006-07-01 | 2013-08-26 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma Obatoclax mesylate (GX15-070MS) - Hodgkin's Lymphoma | Phase 2 | Completed | Gemin X | 13 | 2006-07-01 | 2012-08-06 |
| Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies Obatoclax mesylate (GX15-070MS) - Hematological Malignancies | Phase 1 | Completed | Gemin X | 44 | 2005-10-01 | 2014-05-12 |
| A Phase I/II Study of GX15-070MS in Untreated CLL GX15-070MS - Chronic Lymphocytic Leukemia | Phase 1 | Completed | Gemin X | 26 | 2004-09-01 | 2014-05-12 |
Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lung Neoplasms (1) · Lymphoma (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Mastocytosis, Systemic (1) · Melanoma (1) · Myelodysplastic Syndromes (1) · Primary Myelofibrosis (1) · Small Cell Lung Carcinoma (1)
obatoclax (12) · 1-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxycarbonyloxymethyl)-4-(N'-cyano-N''-(6-(4-chlorophenoxy)hexyl)-N-guanidino)pyridinium (2) · Bortezomib (1) · Docetaxel (1) · EC regimen (1) · Rituximab (1) · Temozolomide (1)
United States (12) · Canada (6) · Bulgaria (1) · Czechia (1) · Hungary (1) · India (1) · Poland (1) · Romania (1) · Serbia (1) · United Kingdom (1)
Jean Viallet, MD (9) · Mark Berger, MD (3) · Srdan Verstovsek, MD (1)
PMID 18931344, PMID 19088047, PMID 20709666, PMID 22383790, PMID 24997137, PMID 25052051, PMID 25285531